1. Home
  2. ABVX vs MCS Comparison

ABVX vs MCS Comparison

Compare ABVX & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABVX
  • MCS
  • Stock Information
  • Founded
  • ABVX 2013
  • MCS 1935
  • Country
  • ABVX France
  • MCS United States
  • Employees
  • ABVX N/A
  • MCS N/A
  • Industry
  • ABVX
  • MCS Movies/Entertainment
  • Sector
  • ABVX
  • MCS Consumer Discretionary
  • Exchange
  • ABVX Nasdaq
  • MCS Nasdaq
  • Market Cap
  • ABVX 451.5M
  • MCS 537.6M
  • IPO Year
  • ABVX N/A
  • MCS N/A
  • Fundamental
  • Price
  • ABVX $6.02
  • MCS $18.47
  • Analyst Decision
  • ABVX Buy
  • MCS Strong Buy
  • Analyst Count
  • ABVX 4
  • MCS 4
  • Target Price
  • ABVX $31.50
  • MCS $23.75
  • AVG Volume (30 Days)
  • ABVX 193.4K
  • MCS 193.5K
  • Earning Date
  • ABVX 03-24-2025
  • MCS 05-06-2025
  • Dividend Yield
  • ABVX N/A
  • MCS 1.51%
  • EPS Growth
  • ABVX N/A
  • MCS N/A
  • EPS
  • ABVX N/A
  • MCS N/A
  • Revenue
  • ABVX $11,172,999.00
  • MCS $704,626,000.00
  • Revenue This Year
  • ABVX $284.20
  • MCS $13.43
  • Revenue Next Year
  • ABVX N/A
  • MCS $4.02
  • P/E Ratio
  • ABVX N/A
  • MCS N/A
  • Revenue Growth
  • ABVX 135.94
  • MCS 3.81
  • 52 Week Low
  • ABVX $4.77
  • MCS $9.56
  • 52 Week High
  • ABVX $14.71
  • MCS $23.16
  • Technical
  • Relative Strength Index (RSI)
  • ABVX 46.21
  • MCS 65.84
  • Support Level
  • ABVX $5.59
  • MCS $16.51
  • Resistance Level
  • ABVX $6.09
  • MCS $18.80
  • Average True Range (ATR)
  • ABVX 0.33
  • MCS 0.46
  • MACD
  • ABVX -0.02
  • MCS 0.19
  • Stochastic Oscillator
  • ABVX 41.15
  • MCS 85.59

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

About MCS Marcus Corporation (The)

Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.

Share on Social Networks: